Tag: Lenacapavir

In June 2025, the FDA approved Yeztugo (lenacapavir), the first and only twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP). For individuals considering this innovative treatment, the pressing question is, "Will insurance cover Yeztugo?".

With a reported first-year list price exceeding $42,000, Sunlenca is a significant investment for heavily treatment-experienced adults with HIV. This sticker shock naturally prompts the question, 'How much is Sunlenca?' for patients, and the answer is complex, depending on a multitude of factors including insurance, financial assistance, and dosing schedules.

Lenacapavir is a first-in-class HIV-1 capsid inhibitor, a novel type of antiretroviral drug approved in 2022 for multidrug-resistant HIV infections. The drug, sold under the brand name Sunlenca®, represents a significant advancement in HIV treatment, and understanding what is Lenacapavir made of provides crucial insight into its innovative function and formulation.

Lenacapavir is a first-in-class HIV capsid inhibitor that can be dosed twice-yearly, marking a significant advancement in the treatment and prevention of HIV. Knowing what is another name for lenacapavir, specifically its brand names, is important as they indicate the medication's intended use.

Following two separate FDA approvals, **is lenacapavir available in the US** for both the treatment of multi-drug resistant HIV and for HIV prevention (PrEP). The latter, approved in June 2025, represents a significant step forward with its injectable administration, offering a novel, long-acting option for eligible individuals.

Lenacapavir is a first-in-class, long-acting HIV capsid inhibitor administered as a twice-yearly injection, a significant advancement in HIV care. Understanding who qualifies for lenacapavir is crucial, as eligibility depends on its intended use for either prevention (PrEP) or treating multi-drug resistant HIV.

Lenacapavir's breakthrough development as a long-acting HIV treatment and prevention medication was the result of a decades-long, collaborative effort between the National Institutes of Health (NIH) and pharmaceutical company Gilead Sciences, not a single individual. So, who invented lenacapavir? The answer lies in this partnership that built on foundational scientific research.

Following its FDA approval in June 2025, Yeztugo (lenacapavir) became the first and only twice-yearly injectable option for HIV pre-exposure prophylaxis (PrEP) in the United States. For those asking, 'Is Yeztugo available?', the answer is yes in the United States, representing a significant advancement in HIV prevention by simplifying the dosing schedule and addressing adherence barriers.

On December 22, 2022, the FDA approved Sunlenca (lenacapavir), a groundbreaking, long-acting medication for heavily treatment-experienced adults living with multidrug-resistant HIV-1. This first-in-class capsid inhibitor offers a twice-yearly subcutaneous injection, revolutionizing treatment options for those with limited alternatives.

Named the "Breakthrough of the Year" by *Science* magazine in 2024, lenacapavir is a first-in-class, long-acting medication used for both the treatment of multi-drug resistant HIV and for pre-exposure prophylaxis (PrEP). It is a capsid inhibitor that acts on the virus in multiple stages of its lifecycle, a novel approach compared to older antiretroviral therapies.